- The stock price of Biofrontera Inc (NASDAQ: BFRI) increased by over 150% during intraday trading today. This is why it happened.
The stock price of Biofrontera Inc (NASDAQ: BFRI) increased by over 150% during intraday trading today. Investors are responding positively to a bullish research report about the company.
Roth Capital analyst Jonathan Aschoff had initiated coverage of Biofrontera with a “Buy” rating and $20 price target. Aschoff believes that Biofrontera is going to meaningfully increase its Ameluz revenue in actinic keratosis as it substantially increases its U.S. sales effort. And Aschoff views Ameluz clinical data as superior to its peers.
The $20 price target imputes a 660.46% upside to the company’s previous closing price.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.